Malignant melanoma and multiple sclerosis therapies: A disproportionality analysis of the FDA adverse event reporting system. - Balshi A; Dempsey JP; Manning N; Leuenberger G; Baber U; Sloane JA (Multiple sclerosis (Houndmills, Basingstoke, England), 2025)